Rockwell Medical Names Jesse Neri as Senior Vice President, Finance
October 18 2023 - 6:00AM
Business Wire
Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a
healthcare company that develops, manufactures, commercializes, and
distributes a portfolio of hemodialysis products to dialysis
providers worldwide, today announced that Jesse Neri has joined the
Company as Senior Vice President, Finance. Mr. Neri will oversee
all aspects of Rockwell Medical's finance organization.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231018055768/en/
Jesse Neri - Senior Vice President,
Finance at Rockwell Medical (Nasdaq:RMTI) (Photo: Business
Wire)
Mr. Neri has over 20 years' experience leading finance functions
at both public and private companies. Prior to joining Rockwell
Medical, he was the head of finance at Hemavant Sciences, a
clinical stage biopharmaceutical company developing therapeutics to
improve the lives of patients with blood disorders and
hematological malignancies. Previously, Mr. Neri served as Senior
Vice President of Finance at Zyla Life Sciences, a public
pharmaceutical company with annual revenue of $80 million. As a
member of the senior management team, Mr. Neri was responsible for
all aspects of its finance organization including SEC reporting,
audit, controllership, and strategic planning. While at Zyla, he
played a pivotal role in multiple product acquisitions, financings,
commercial product launches and regulatory approvals, along with
Zyla's acquisition by Assertio Therapeutics in May 2020. Prior to
Zyla, Mr. Neri served as Vice President of Financial Planning and
Analysis at Symphony Health Solutions, a private equity-backed
market research company with revenues over $200 million. Mr. Neri
received a B.S., Business Administration of Finance from Villanova
University and an M.B.A. from Drexel University LeBow School of
Business.
"Jesse's extensive experience leading finance organizations
within revenue-generating, growth-oriented healthcare businesses
will be valuable to Rockwell Medical as we contemplate various
avenues of expansion and growth," said Mark Strobeck, Ph.D.,
President and CEO at Rockwell Medical. "Additionally, Jesse's
expertise will enhance our ability to continue strengthening our
financial and operating infrastructure while advancing our ability
to meet our strategic objectives."
“I am thrilled to be joining Rockwell Medical as its new head of
finance at such an exciting time in the Company's history," said
Mr. Neri. "Rockwell Medical continues to improve its balance sheet
and expand its leadership position in the renal healthcare space. I
am excited to be part of a team that is focused on innovative,
long-term growth strategies that have the potential to positively
impact patients and shareholders around the globe."
The Compensation Committee of the Company’s Board of Directors
approved the grant of stock options to purchase 75,000 shares of
the Company’s common stock to Mr. Neri (the “Inducement Grant”) on
October 16, 2023 (the “Grant Date”). The Inducement Grant has been
granted outside of the Company’s 2018 Long Term Incentive Plan
(“Plan”) but remains subject to the terms and conditions of such
Plan. The Inducement Grant was granted as an inducement material to
Mr. Neri entering into employment with Rockwell Medical in
accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement
Grant has an exercise price per share that is equal to the closing
price of the Company’s common stock on the Grant Date. The
Inducement Grant will vest 25% on each of the first four
anniversaries of the Grant Date until fully vested, subject to Mr.
Neri’s continued employment through the applicable vesting
dates.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company
that develops, manufactures, commercializes, and distributes a
portfolio of hemodialysis products for dialysis providers
worldwide. Rockwell Medical's mission is to provide dialysis
clinics and the patients they serve with the highest quality
products supported by the best customer service in the industry.
Rockwell is focused on innovative, long-term growth strategies that
enhance its products, its processes, and its people, enabling the
Company to deliver exceptional value to the healthcare system and
provide a positive impact on the lives of hemodialysis patients.
Hemodialysis is the most common form of end-stage kidney disease
treatment and is typically performed at freestanding outpatient
dialysis centers, hospital-based outpatient centers, skilled
nursing facilities, or in a patient’s home. Rockwell Medical's
products are vital to vulnerable patients with end-stage kidney
disease, and the Company is relentless in providing unmatched
reliability and customer service. Rockwell Medical is the second
largest supplier of acid and bicarbonate concentrates for dialysis
patients in the United States and has the vision of becoming the
leading global supplier of hemodialysis concentrates. Certified as
a Great Place to Work® in 2023, Rockwell Medical is Driven to
Deliver Life-Sustaining Dialysis SolutionsTM. For more information,
visit www.RockwellMed.com.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as, "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue," "could,"
"can," "would," "develop," "plan," "potential," "predict,"
"forecast," "project," "intend," "look forward to," "remain
confident," “are determined,” “are on track,” “are resolute in our
vision,” "work to," "drive towards," “focused on,” or the negative
of these terms, and similar expressions, or statements regarding
intent, belief, or current expectations, are forward looking
statements. There can be no assurance that Rockwell Medical will
become the leading global supplier of hemodialysis concentrates,
expand or maintain its customer relationships going forward, or
that Mr. Neri's expertise will help Rockwell Medical achieve its
strategic goals. While Rockwell Medical believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties
(including, without limitation, those set forth in Rockwell
Medical's SEC filings), many of which are beyond our control and
subject to change. Actual results could be materially different.
Risks and uncertainties include, but are not limited to those risks
more fully discussed in the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31, 2022, as such
description may be amended or updated in any future reports we file
with the SEC. Rockwell Medical expressly disclaims any obligation
to update our forward-looking statements, except as may be required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018055768/en/
Heather R. Hunter SVP, Chief Corporate Affairs Officer (248)
432-1362 IR@RockwellMed.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024